To the full analysis
CVS Health stock: growth
CVSCVS Health reported $402.07B in revenue for fiscal 2025, up 7.8% on the prior year, up 8.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.4%
per year from 2006 to 2025, per share 9.8%
Earnings (Annual rate)
1.4%
per year from 2006 to 2025, per share −0.9%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.4% | 10.1% | 12.4% |
| Revenue per share | 9.1% | 8.8% | 9.8% |
| Earnings | −24.4% | −10.3% | 1.4% |
| Earnings per share | −23.9% | −11.3% | −0.9% |
| Free cash flow | −10.3% | 2.4% | no data |
| Free cash flow per share | −9.7% | 1.1% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $43.82B | $1.37B | −$26.5M |
| 2007 | $76.33B | $2.64B | $1.42B |
| 2008 | $87.47B | $3.21B | $1.77B |
| 2009 | $98.22B | $3.7B | $1.49B |
| 2010 | $95.78B | $3.43B | $2.77B |
| 2011 | $107.08B | $3.46B | $3.98B |
| 2012 | $123.12B | $3.86B | $4.64B |
| 2013 | $126.76B | $4.59B | $3.8B |
| 2014 | $139.37B | $4.64B | $6B |
| 2015 | $153.29B | $5.24B | $6.17B |
| 2016 | $177.55B | $5.32B | $7.92B |
| 2017 | $184.79B | $6.62B | $6.09B |
| 2018 | $194.58B | −$594M | $6.83B |
| 2019 | $256.78B | $6.63B | $10.39B |
| 2020 | $268.71B | $7.18B | $13.43B |
| 2021 | $292.11B | $8B | $15.75B |
| 2022 | $322.47B | $4.31B | $13.45B |
| 2023 | $357.78B | $8.34B | $10.4B |
| 2024 | $372.81B | $4.61B | $6.33B |
| 2025 | $402.07B | $1.77B | $7.81B |
Revenue by segment
How CVS Health Corp. makes its money and how that has shifted. Names are as the company reports them.
- Pharmacy Revenue57%
- Premiums34%
- Front Store Revenue5%
- Other4%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacy Revenue | $164.85B | $165.9B | $171.29B | $184.62B | $205.12B | $223.45B | $210.27B | $229.03B | 57% |
| Premiums | $8.18B | $63.12B | $69.36B | $76.13B | $85.33B | $99.19B | $122.9B | $134.75B | 33.5% |
| Front Store Revenue | $19.06B | $19.42B | $19.66B | $21.32B | $22.78B | $22.46B | $21.52B | $21.46B | 5.3% |
| Other | $2.5B | $8.33B | $8.4B | $10.05B | $9.24B | $12.67B | $18.12B | $16.83B | 4.2% |
| Total revenue | $194.58B | $256.78B | $268.71B | $292.11B | $322.47B | $357.78B | $372.81B | $402.07B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.